Luyan Pharmaceutical announced that its revenue for the first half of 2026 was 10.583 billion yuan, an increase of 1.75% over the previous year. Net profit attributable to shareholders of listed companies was 143 million yuan, a year-on-year decrease of 7.46%. After deducting non-net profit of 138 million yuan, a year-on-year decrease of 9.88%. The company plans not to pay cash dividends, bonus shares, and not to use the Provident Fund to increase share capital.

Luyan Pharmaceutical announced that its revenue for the first half of 2026 was 10.583 billion yuan, an increase of 1.75% over the previous year. Net profit attributable to shareholders of listed companies was 143 million yuan, a year-on-year decrease of 7.46%. After deducting non-net profit of 138 million yuan, a year-on-year decrease of 9.88%. The company plans not to pay cash dividends, bonus shares, and not to use the Provident Fund to increase share capital.